PubMed Health⌕ Search

Biomedical subjects

V B Sergienko

Publications and source records attributed to V B Sergienko.

At least 19 recordsLinked to original sources
PubMed2006

[Cardiac sympathetic innervation in patients with ventricular arrhythmias: an assessment by 123I-metaiodobenzylguanidine scintigraphy].

The aim of this study was to determine the state of sympathetic innervation in patients with ventricular arrhythmias (VA) using 123I-metaiodobenzylguanidine 123I -MIBG) scintigraphy. Fifty six patients (26 men and 30 women, mean age 37.4+/-11,6) underwent single-photon emission computed tomography (SPECT) imaging and planner scintigraphy after injection of 123I-MIBG (activity 148 MBq). They form three groups. Thirty patients with idiopathic VA (IVA) were included in group I: 14 patients with ventricular extrasystoles (VE) and 16 - with ventricular tachycardias (VT). Group II was formed by 17 patients (with dilated cardiomyopathy, n=7 and chronic myocarditis, n=10), 6 of them had VE and 11 - VT. The control group III was formed by 9 healthy subjects with structurally normal heart without VA. We analyzed early (30 minutes) and delayed (4 hours) images after 123I-MIBG administration. The global sympathetic activity (SA) was assessed by heart/mediastinum ratio and washout rate. Regional SA was assessed by extent and severity of defect. In group I 25 of 30 patients (83.3%) had regional SA abnormalities significantly different from controls (p<0.001). At the same time global uptake of 123I-MIBG in this group was not affected. In group II regional SA abnormalities were revealed in all patients (100%) and global reduction of 123I-MIBG uptake - in 14 patients (82.4%). Regional and global SA abnormalities in group II were different from controls (p<0.0001) and patients with IVA (p<0.001). There was no difference in SA abnormalities between patients with VE and VT. Our results suggest that patients with different VA have abnormalities of sympathetic innervation, including patients with structurally normal heart.

3-Iodobenzylguanidine↗
PubMed2005

[Body mass loss due to orlistat therapy and multiple factors of cardiovascular risk].

AIM: To study effects of body mass loss due to orlistat on carbohydrate and lipid metabolism, insulin resistance, 24-h profile of arterial pressure (AP), left ventricular myocardial hypertrophy, brain perfusion in patients with metabolic syndrome (MS). MATERIAL AND METHODS: Thirty middle-aged patients with MS entered the trial. They received orlistat in a dose 120 mg twice a day for 24 weeks. Before and after the treatment the patients' carbohydrate and lipid metabolism, insulin resistance were studied, 24-h monitoring of arterial pressure, echo-cardiography were made. Brain perfusion was studied with single-photon emission computed tomography in 18 patients. Results. All the patients lost much weight. This was accompanied with improved indices of AP profile, metabolism of carbohydrates and lipids, insulin resistance, left ventricular hypertrophy, brain perfusion. Conclusion. Orlistat treatment weakens basic factors of cardiovascular risk.

Adult↗
PubMed2005

[Cerebral perfusion in patients with metabolic syndrome].

Cerebral perfusion was studied in patients with arterial hypertension combined with metabolic syndrome and diabetes mellitus type II. The data is compared to the results obtained for patients with a single disorder--metabolic syndrome, diabetes mellitus type II and arterial hypertension without metabolic alterations. It is shown that patients with disregulation of carbohydrate and lipid metabolism are more vulnerable to cerebral blood supply alterations. A level of perfusion was the same in patients with metabolic syndrome and diabetes mellitus type II. Besides, an acetazolamide application revealed that patients with metabolic syndrome had reduced cerebral vascular autoregulation.

Acetazolamide↗
PubMed2005

[Primary prophylaxis of cerebrovascular complications in patients with metabolic syndrome].

AIM: To study effects of antihypertensive therapy with bisoprolol and actovegin on cerebral perfusion in patients with metabolic syndrome. MATERIAL AND METHODS: Thirty patients (18 women and 12 men) with metabolic syndrome and mild arterial hypertension took bisoprolol alone in a dose 5-10 mg/day, and fifteen patients received combined therapy (bisoprolol and actovegin) for 12 weeks. Before the study and 12 weeks later measurements were made of carbohydrate and lipid metabolism, single photon emission computed tomography investigated brain perfusion. RESULTS: Improvement of brain perfusion was observed after both monotherapy with bisoprolol and its combination with actovegin. CONCLUSION: Monotherapy with bisoprolol and bisoprolol combination with actovegin improved brain perfusion but the combination was more effective.

Adult↗
PubMed2004

[Cerebrovascular complications in metabolic syndrome: possible approaches to decrease risk].

AIM: To compare brain perfusion in hypertensive patients with diabetes mellitus type 2 (DM2) or metabolic (MS) syndrome and hypertensive patients without clinicobiochemical signs of DM2 or MS; to study enoxaparin effects on brain perfusion in DM2 and arterial hypertension (AH). MATERIAL AND METHODS: Seventy patients included in the study were divided into three groups: 30 patients with DM2 and AH (group 1), 30 patients with MS and AH (group 2) and 10 AH patients without manifestations of MS or DM2 (group 3). All the patients have undergone single-photon emission computed tomography (SPECT) of the brain, carbohydrate and lipid metabolism were examined. RESULTS: Deterioration of brain perfusion was more prominent in DM2 and MS patients with AH than in hypertensive patients with normal metabolism. Stress test with acetasolamide revealed defective autoregulation of cerebral blood flow in hypertensive patients with DM2. A 6-week therapy with enoxaparin significantly improved brain perfusion in hypertensive patients with DM2. CONCLUSION: Enoxaparin treatment of hypertensive DM2 and MS patients with abnormal perfusion of the brain can be used for prevention of cerebrovascular complications.

Adult↗
PubMed2004

[Impairment of cardiac sympathetic function in patients with acute myocardial infarction and unstable angina].

AIM: To assess the state of sympathetic innervation of the heart in patients with acute coronary syndrome. MATERIAL: Patients with Q-myocardial infarction (MI, n=36), non-Q-MI (n=13), and unstable angina (UA, n=9). METHODS: Each subject underwent single-photon emission computed tomography (SPECT) and planar scintigraphy using iodine-123 metaiodobenzylguanidine ((123)I-MIBG) for assessment of cardiac sympathetic function. We analyzed early (15 minutes) and delayed (4 hours) images after (123)I-MIBG administration. Resting (99m)Tc-MIBI myocardial scintigraphy was performed for evaluation of myocardial perfusion. Location, extent (%) and severity (Un.) of defects were determined using < > program. (123)I-MIBG did not accumulate in myocardium of 3.5% patients. All other patients demonstrated (123)I-MIBG accumulation defects. These defects were colocolized with (99m)Tc-MIBI uptake abnormalities. However both extent and severity of sympathetic innervation defects exceeded those of perfusion defects in all patients. Mean extent and severity of sympathetic neuronal damage areas were the greatest in patients with Q-MI (41+/-8% and 1119+/-377 Un. respectively) and the least in patients with UA (22+/-12% and 602+/-353 Un., respectively). On the contrary the mean extent of areas with sympathetic endings dysfunction but normal perfusion was the largest in UA group and the least in Q-MI group (18+/-11 and 10+/-7%, respectively, p<0,05). CONCLUSION: Impairment of cardiac sympathetic function in patients with acute coronary syndrome could be detected by SPECT with (123)I-MIBG. Locations of (123)I-MIBG and (99m)Tc-MIBI defects were similar but sympathetic dysfunction areas were larger than areas with reduced perfusion. This result suggests higher sensitivity of sympathetic endings to ischemia compared with cardiomyocytes. Myocardial areas with sympathetic endings dysfunction but normal perfusion can be defined as myocardium at risk.

3-Iodobenzylguanidine↗
PubMed2004

[Comparative effectiveness of different methods of diagnosis and correction of impaired portal circulation].

The diagnostic effectiveness of X-ray radionuclide and ultrasound determination of portal blood flow and the impact of different treatments on the blood flow were evaluated in 76 patients with hepatic cirrhosis. The treatment regimens were used propranolol (Group 1), isosorbide-5-mononitrate (monosan) (Group 2), and a combined therapy with propranolol in combination with diuretics and a course of intravenous laser irradiation (Group 3). In terms of both clinical and laboratory parameters and the status of portal circulation, the highest effect was observed in the patients receiving the combined therapy.

Antihypertensive Agents↗
PubMed2003

[Evaluation of myocardial perfusion in patients with hypertrophic cardiomyopathy in comparison with clinical and echocardiographic data].

AIM: To study peculiarities of myocardial perfusion in patients with hypertrophic cardiomyopathy (HCMP) in correlation with clinical and echocardiographic data. MATERIAL AND METHODS: 62 patients with HCMP (23 females and 39 males, mean age 44.4 +/- 11.2 years, the disease duration 13.0 +/- 10.4 years) have undergone ECG, 24-h ECG monitoring, echocardiography, perfusion scintigraphy of the myocardium with 99m-TcMIBI at rest and in combination with bicycle ergometry. The patients were divided into two groups: 35 patients of group 1 had moderate left ventricular hypertrophy (the septal thickness in diastole under 20 mm; 27 patients of group 2 had severe hypertrophy (the thickness was over 20 mm). RESULTS: Dyspnea and syncopal states occurred more frequently in patients from group 2. They also had a higher functional class of heart failure (2.0 +/- 0.8 and 1.2 +/- 0.7 for group 1 and 2, respectively, p < 0.05). Cardiac performance was significantly higher in patients of group 1. The size of the left atrium, left ventricular myocardium mass, the septal thickness and thickness of posterior wall of the left ventricle, gradient of pressure in the outflow tract of the left ventricle proved higher in patients of group 2. Deep stable defects of myocardial perfusion were detected in 5 (15%) patients of group 1 and 10 (37%) patients of group 2. Transient defects of myocardial perfusion were found in 9 (26%) patients of group 1 and 12 (44%) patients of group 2. The index of myocardial ischemia in group 1 patients was significantly lower than in patients of group 2 (3.5 +/- 2.2 and 8.3 +/- 2.5, respectively, p < 0.05). CONCLUSION: Patients with severe hypertrophy of the left ventricle had severe clinical picture, low exercise tolerance, marked hemodynamic changes, more frequent defects of left ventricular perfusion defects compared to patients with moderate hypertrophy of the left ventricular myocardium.

Adult↗
PubMed2003

[Preliminary data on combined assessment of tolerance to exercise, left ventricular contractile function in ischemic heart disease patients taking bradycardic agents].

AIM: To study effects of bradicardia induced by atenolol, diltiazem and ivabradin on exercise tolerance, myocardial perfusion and left ventricular contractile function in patients with stable angina pectoris. MATERIAL AND METHODS: The trial included 7 male patients aged 57 +/- 2.6 years with coronary heart disease, stable angina of functional class II free of cardiac failure and severe arterial hypertension, with a positive and reproducible VEM test after therapy discontinuation. For 10 consecutive days with 5-day intervals, all the patients received atenolol, diltiazem, ivabradin in doses lowering heart rate at rest by 20% from the initial level. Before the treatment all the patients were studied with VEM test, perfusion synchronized single-photon emission computerized tomoscintigraphy of the myocardium (PSSPECT) at rest and exercise. On day 10 of each drug intake PSSPECT and VEM test were performed if the expected heart rate was achieved. RESULTS: Each of the studied drugs resulted in a 22-24% reduction in the heart rate at rest accompanied by a significant rise in exercise tolerance, improvement of performance and myocardial perfusion. There were no significant changes in left ventricular contractility. CONCLUSION: A 20% reduction in resting heart rate due to monotherapy with drugs having a bradicardic effect leads to positive changes in exercise tolerance and myocardial perfusion.

Atenolol↗
PubMed2003

[Effect of restoration of coronary blood flow on dynamics of myocardial perfusion and function in patients with acute myocardial infarction. Data of gated technetium-99m-sestamibi SPECT].

Effects of coronary blood flow restoration on dynamics of myocardial perfusion and function were studied in 50 patients with acute myocardial infarction during 6-month follow-up. Gated SPECT with 99mTc-MIBI (G-SPECT) was performed before onset of reperfusion procedures, in 24 hours, 10 days, 1 and 6 months. In patients with successful reperfusion (n=36) perfusion defect (PD) size decreased by 6.78+/-0.97% (p<0.001) and its severity by 221.3+/-85 std (p<0.001) in 24 hours. In 10 days PD size decreased by 3.9+/-0.88% (r<0.05) and severity by 149+/-39 std (p<0.05), whereas in 1 month PD size decreased by 2,18+/-1,4% (p<0.05), PD severity by 146.3+/-67 std (p<0.05). Successful reperfusion was associated with improvement of contractility: left ventricular ejection fraction increased by 3% (p<0.05) on day 10 of the disease. In patients with failed reperfusion PD size and severity decreased in 10 days by 4.8+/-4.2%, p<0.05, and 276+/-75 std, p<0.05, respectively, in 6 months PD size decreased by 3.1+/-0.9%, p<0.05, left ventricular ejection fraction did not change during follow-up. We conclude that successful reperfusion therapy promotes restoration of myocardial perfusion and improvement of its contractility.

Angioplasty, Balloon, Coronary↗
PubMed2002

[Viable myocardium: comparative evaluation of surgical and pharmacological treatment of patients with ischemic heart disease, post-infarct cardiosclerosis and chronic cardiac failure].

AIM: To compare surgical and drug therapies of viable myocardium in IHD patients with left ventricular dysfunction (LVD), to show how to choose between them basing on the presence or absence of viable myocardium in the dyssenergy zones in such patients. MATERIAL AND METHODS: The study enrolled 55 IHD patients with postinfarction cardiosclerosis, left ventricular ejection fraction under 35%, circulatory disorder class I-III (NYHA classification). Coronary artery bypass operation (CABO) was made in 24 patients, 31 patients received drugs. The examination included dobutamin echo-CG, perfusion myocardial scintigraphy. Viability of the myocardium was assessed before and 6 months after the treatment. RESULTS: The patients were divided by the treatment and number of segments of viable myocardium: group 1--patients with viable myocardium subjected to CABO, group 2--patients with non-viable myocardium subjected to CABO, group 3--patients with viable myocardium treated with drugs, group 4--patients with non-viable myocardium treated with drugs. The greatest rise in LV EF, reduction of the end diastolic volume, end systolic volume of the left ventricle and functional class was observed in group 1. In group 2 these parameters changed less than in group 3. Patients of groups 2 and 4 were similar by parameters of LV global contractility. CONCLUSION: Improvement of central hemodynamics and functional class was the greatest in IHD patients after CABO having viable myocardium. If myocardium is not viable surgical treatment has no advantage over conservative in improvement of the pump cardiac function and is inferior to pharmacological treatment in effect on myocardium function in patients with viable myocardium in dyssynergia zones.

Adrenergic beta-Antagonists↗
PubMed2002

[Atenolol induced bradycardia in patients with stable angina: effects on exercise tolerance, myocardial perfusion and left ventricular contractility].

AIM: To assess effects of atenolol-induced heart rate decrease on myocardial perfusion, left ventricular contractility and tolerance to exercise in patients with chronic coronary artery disease. MATERIAL AND METHODS: Twenty eight men (mean age 54,5-/+9,2 years) with stable class I-III angina and positive reproducible result of bicycle exercise test underwent rest/stress 99mTc-MIIBI gated single-photon emission computed tomography (SPECT) before and after 10 days of administration of atenolol (20 patients) or placebo (8 patients). Dose of atenolol was titrated to achieve at least 15% decrease of heart rate from baseline. RESULTS: After 10 days of treatment with atenolol heart rate decreased from 78-/+3.1 to 59-/+1.1 bpm (p=0.01), whereas in placebo group there were no significant changes. Compared with placebo, treatment with atenolol was associated with significant decreases in extent and severity of perfusion defects, ischemic score and number of ischemic segments. No significant changes of parameters of left ventricular contractility occurred. Treatment with atenolol was associated with symptomatic improvement and increase of the total exercise time. CONCLUSION: Heart rate lowering during monotherapy with atenolol was associated with improvement of myocardial perfusion and tolerance to exercise.

Adrenergic beta-Antagonists↗
PubMed2001

[Myocardial microcirculation in patients with systemic lupus erythematosus].

AIM: To examine myocardial microcirculation in patients with SLE. MATERIAL AND METHODS: Examination of 21 SLE patients consisted of perfusion tomoscintigraphy of the myocardium with Tl-201 at rest and in combination with bicycle exercise. Various protocols were used. RESULTS: The majority of SLE patients had resting disorders of myocardial perfusion: 5 had macrofocal scar lesion of the myocardium, 12 had disorders typical for small-focal myocardial fibrosis. Normal distribution of the perfusion occurred in 4 cases. Tomoscintigraphy performed in combination with exercise test revealed in 11 of 15 patients transient perfusion disturbances reflecting transient myocardial ischemia. One third of the patients had changes characteristic of myocardial ischemia due to coronary atherosclerosis. CONCLUSION: SLE patients have disorders of myocardial perfusion including those characteristic of scar lesion, small-focal cardiofibrosis and transient myocardial ischemia of different genesis: due to disorders in microcirculation and atherosclerotic lesion of major coronary arteries.

Adult↗